Skip to main content
Journal cover image

Defining COVID-19-associated pulmonary aspergillosis: systematic review and meta-analysis.

Publication ,  Journal Article
Kariyawasam, RM; Dingle, TC; Kula, BE; Vandermeer, B; Sligl, WI; Schwartz, IS
Published in: Clin Microbiol Infect
July 2022

BACKGROUND: Pulmonary aspergillosis may complicate coronavirus disease 2019 (COVID-19) and contribute to excess mortality in intensive care unit (ICU) patients. The disease is poorly understood, in part due to discordant definitions across studies. OBJECTIVES: We sought to review the prevalence, diagnosis, treatment, and outcomes of COVID-19-associated pulmonary aspergillosis (CAPA) and compare research definitions. DATA SOURCES: PubMed, Embase, Web of Science, and MedRxiv were searched from inception to October 12, 2021. STUDY ELIGIBILITY CRITERIA: ICU cohort studies and CAPA case series including ≥3 patients were included. PARTICIPANTS: Adult patients in ICUs with COVID-19. INTERVENTIONS: Patients were reclassified according to four research definitions. We assessed risk of bias with an adaptation of the Joanna Briggs Institute cohort checklist tool for systematic reviews. METHODS: We calculated CAPA prevalence using the Freeman-Tukey random effects method. Correlations between definitions were assessed with Spearman's rank test. Associations between antifungals and outcome were assessed with random effects meta-analysis. RESULTS: Fifty-one studies were included. Among 3297 COVID-19 patients in ICU cohort studies, 313 were diagnosed with CAPA (prevalence 10%; 95% CI 8%-13%). Two hundred seventy-seven patients had patient-level data allowing reclassification. Definitions had limited correlation with one another (ρ = 0.268-0.447; p < 0.001), with the exception of Koehler and Verweij (ρ = 0.893; p < 0.001); 33.9% of patients reported to have CAPA did not fulfill any research definitions. Patients were diagnosed after a median of 8 days (interquartile range 5-14) in ICUs. Tracheobronchitis occurred in 3% of patients examined with bronchoscopy. The mortality rate was high (59.2%). Applying CAPA research definitions did not strengthen the association between mould-active antifungals and survival. CONCLUSIONS: The reported prevalence of CAPA is significant but may be exaggerated by nonstandard definitions.

Duke Scholars

Altmetric Attention Stats
Dimensions Citation Stats

Published In

Clin Microbiol Infect

DOI

EISSN

1469-0691

Publication Date

July 2022

Volume

28

Issue

7

Start / End Page

920 / 927

Location

England

Related Subject Headings

  • Pulmonary Aspergillosis
  • Microbiology
  • Intensive Care Units
  • Humans
  • Critical Care
  • COVID-19
  • Antifungal Agents
  • Adult
  • 3207 Medical microbiology
  • 3202 Clinical sciences
 

Citation

APA
Chicago
ICMJE
MLA
NLM
Kariyawasam, R. M., Dingle, T. C., Kula, B. E., Vandermeer, B., Sligl, W. I., & Schwartz, I. S. (2022). Defining COVID-19-associated pulmonary aspergillosis: systematic review and meta-analysis. Clin Microbiol Infect, 28(7), 920–927. https://doi.org/10.1016/j.cmi.2022.01.027
Kariyawasam, Ruwandi M., Tanis C. Dingle, Brittany E. Kula, Ben Vandermeer, Wendy I. Sligl, and Ilan S. Schwartz. “Defining COVID-19-associated pulmonary aspergillosis: systematic review and meta-analysis.Clin Microbiol Infect 28, no. 7 (July 2022): 920–27. https://doi.org/10.1016/j.cmi.2022.01.027.
Kariyawasam RM, Dingle TC, Kula BE, Vandermeer B, Sligl WI, Schwartz IS. Defining COVID-19-associated pulmonary aspergillosis: systematic review and meta-analysis. Clin Microbiol Infect. 2022 Jul;28(7):920–7.
Kariyawasam, Ruwandi M., et al. “Defining COVID-19-associated pulmonary aspergillosis: systematic review and meta-analysis.Clin Microbiol Infect, vol. 28, no. 7, July 2022, pp. 920–27. Pubmed, doi:10.1016/j.cmi.2022.01.027.
Kariyawasam RM, Dingle TC, Kula BE, Vandermeer B, Sligl WI, Schwartz IS. Defining COVID-19-associated pulmonary aspergillosis: systematic review and meta-analysis. Clin Microbiol Infect. 2022 Jul;28(7):920–927.
Journal cover image

Published In

Clin Microbiol Infect

DOI

EISSN

1469-0691

Publication Date

July 2022

Volume

28

Issue

7

Start / End Page

920 / 927

Location

England

Related Subject Headings

  • Pulmonary Aspergillosis
  • Microbiology
  • Intensive Care Units
  • Humans
  • Critical Care
  • COVID-19
  • Antifungal Agents
  • Adult
  • 3207 Medical microbiology
  • 3202 Clinical sciences